Management, Economics and Quality Assurance in Pharmacy

Today community and hospital pharmacies worldwide (including Nigeria) experience an increased demand for extemporaneous preparations. Due to “per body weight” dosing system, difficulty in swallowing, frailty in organs of metabolism and unavailability of required dosage forms, the reconstitution/tailoring of medications to individual patients needs has become necessary. In Nigeria most (>95 %) of the extemporaneously prepared medications are oral dosage forms. It is a common practice for these medications to be prepared from a commercially available oral solid dosage form by crushing tablets or mixing contents with a dispersion medium (base/vehicle). The aim of the work was to analyse frequently compounded prescriptions in south-south geopolitical region of Nigeria, bases/vehicles used in compounding and stability study concerns of compounded preparations. For this purpose a survey of prescriptions in hospital pharmacies in the south-south geopolitical region of Nigeria was conducted. The prescriptions that required extemporaneous preparation were selected and sorted into active pharmaceutical ingredients (APIs), doses, regime and duration of treatment. Most prescribed preparations that required compounding include antibiotics (24.9 %) and drugs indicated for cardiovascular diseases (60.0 %). While the treatment duration prescribed for extemporaneous preparations ranged from two days to a month, the most recurring duration was one week. Syrups of ascorbic acid and Vitamin B Complex were occasionally used as bases for compounding, but stability study of extemporaneous preparations made from these medicated
syrups is yet to be conducted in Nigeria. APIs as part of commercial drugs were mostly (92.9%) used in compounding. Stability study of extemporaneous preparations in Nigeria is an urgent problem that needs to be resolved.

Extemporaneous preparations; active pharmaceutical ingredient; base/vehicle; survey; syrups; stability

Aghahowa S. E. Pattern of extemporaneous prescriptions and preparations in a tertiary health institution: a five-year assessment / S. E. Aghahowa, J. O. Egharevba, B. E. Erhagbe, F. Okoh // Intern. J. of Pharm. Compounding. – 2013. – № 5 (17). – Р. 432-435.

Bolisetty S. Omeprazole 2 mg/ml suspension. South eastern Sydney local health district / S. Bolisetty, E. Jozsa. [Electronic resource].– Режим доступа: http://www.seslhd.health. nsw.gov.au/rhw/newborn_care/guidelines/medication/pdf/omeprazole.pdf.

British Pharmaceutical Codex (1979) 11th Ed.– London: The Pharmaceutical Press, 1979. –P. 791.

Chan D. S. Degradation of captopril in solutionscompounded from tablets and standardpowder / D. S. Chan, A. K. Sato, J. R. Claybaugh// Am. J. Hosp. Pharm. – 1994. – № 51.– Р. 1205-1207.

Crawford S. Y. Extemporaneous compounding activities and the associated informational needsof pharmacist / S. Y. Crawford, S. R. Dombrowski// Am. J. Hosp. Pharm. – 1991. – № 48. – Р. 1205-1210.

Davit B. M. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and DrugAdministration / [B. M. Davit, P. E. Nwaka ma, G. I. Buehler et al.] // Ann. Pharmacother.– 2009. – № 43 (10). – Р. 1583-1597.

Elujoba A. A. Traditional medicine development for medical and dental primary health care delivery system in Africa / A. A. Elujoba, O. M. Odeleye, C. M. Ogunyemi // African J. of Traditional, Complementary and Alternative Med. – 2005. – № 2 (1). – Р. 46-61.

Glass B. D. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products / B. D. Glass, A. Haywood // J. of Pharmacy and Pharm. Sci. – 2006. – № 9. – P. 398-426.

Jackson M. Handbook of Extemporaneous Preparation: A Guide to Pharmaceutical Compounding / M. Jackson, A. Lowey. – London: Pharmaceutical Press, 2010. – 464 p.

Kisangau D. P. Traditional knowledge, use practices and conservation of medicinal plants for HIV/AIDS care in rural Tanzania / [D. P. Kisangau, T. M. Herrmann, H. V. Lyaruu et al.] // Ethnobotany Res. and Applications. – 2011. – № 9. – Р. 43-58.

Li Y. Y. Development of a hydrochlorothiazide 0,5 mg/mL oral solution for children / Y. Y. Li, D. J. Postma, H. W. G. Wagenaar // EAHP Congress, Paris, 2013. [Electronic resource]. – Режим доступа: http://www.stabilis.org/ FichesBiblio/ 3399.pdf.

Loyd V. A. Current & Practical Compounding Information for the Pharmacist / V. A. Loyd // Secundum Artem. – 2012. – № 17 (1). – Р. 1-4.

Lye M. Y. Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids / [M. Y. Lye, K. L. Yow, L. Y. Lim et al.] // Am. J. Health-Syst. Pharm. – 1997. – № 54. – Р. 2483-2487.

MOH Extemporaneous Formulary 2011 [Електронний ресурс]. – Режим доступу: http://www.pharmacy.gov.my/v2/sites/default/files/document-upload/mohextemporaneousformulary2011.pdf

Nahata M. C. Stability of amlodipine mesylate in two liquid dosage form / M. C. Nahata, R. S. Morosco, T. F.Hipple // J. Am. Pharm. Assoc. – 1999. – № 39. – Р. 375-377.

Nahata M. C. Stability of captopril in liquid containing ascorbic acid or sodium ascorbate / M. C. Nahata, R. S.Morosco, T. F. Hipple // Am. J. Hosp. Pharm. – 1994. – № 51. – Р. 1707-1708.

Pauline E. O. Complementary and alternative medicine in the management of hypertension in an urban Nigerian community / E. O. Pauline, E. O. Bernard // BMC Complementary and Alternative Medicine. – 2010. – № 10. – Р. 1-9.

Rasaq A. Treatment non-adherence among patients with poorly controlled type 2 diabetes in ambulatory care settings in south western Nigeria / A. Rasaq, O. F. Titilayo // Afr. Health Sci. – 2014. – № 14 (1). – Р. 1-10.

Trissel L. A. Trissel’s stability of compounded formulations. – 4th ed. – Washington, DC: American Pharmacists Association, 2009. – 654 р.

United Nations Framework Convention on Climate Change: Nigeria’s intended nationally determined contribution, Cairo 2015. [Електронний ресурс]. – Режим доступу: http://www4.unfccc.int/submissions/INDC/ Published%20Documents/Nigeria/1/Approved% 20Nigeria’s%20INDC_271115.pdf.

—